When President Joe Biden’s budget comes out on Thursday, expect to see a big, potentially multi-billion-dollar proposal to really take a crack at curing more … ...
Count Regeneron as the latest big biopharma company to pitch in on finding a therapy to combat the Wuhan virus.
Long after many analysts had given Merck’s CETP heart drug anacetrapib up for dead following a slate of expensive burials for the first three drugs … ...
As Regeneron moves its antibody cocktail into Phase II/III trials testing REGN-COV2 as a treatment for both hospitalized and non-hospitalized patients with Covid-19, the … ...
Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Back in the summer of 2019, Carl Hansen left his post as a professor at the University of British Columbia to go full time as … ...
House Democrats on Thursday fell in line behind Speaker Nancy Pelosi’s (D-CA) drug pricing bill, voting for its passage 230-192, with two Republicans voting for … ...
The use of fludarabine was fingered as a key culprit in the deaths of several patients taking Juno’s lead CAR-T therapy, but it’s an … ...
When it comes to experimental cholesterol drugs, all eyes this year are on inclisiran, the $9.7 billion RNAi drug Novartis hopes will replace and … ...
Celgene works to calm down anxious investors, promising to re-file ozanimod at the FDA in early 2019
For weeks now, analysts have been fretting over the future of Celgene’s $CELG multiple sclerosis drug ozanimod. Turned away at the FDA’s ...
Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results